Free Trial
NASDAQ:LEXX

Lexaria Bioscience 7/14/2025 Earnings Report

Lexaria Bioscience logo
$0.83 -0.01 (-1.07%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.83 0.00 (-0.48%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexaria Bioscience EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Lexaria Bioscience Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.17 million
Beat/Miss
Missed by -$4.00 thousand
YoY Revenue Growth
N/A

Lexaria Bioscience Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lexaria Bioscience Earnings Headlines

HC Wainwright Expects Lower Earnings for Lexaria Bioscience
LEXX: Third Quarter Results
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
LEXX - Lexaria Bioscience Corp Dividends - Morningstar
See More Lexaria Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email.

About Lexaria Bioscience

Lexaria Bioscience (NASDAQ:LEXX) operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

View Lexaria Bioscience Profile

More Earnings Resources from MarketBeat